Default: The Lancet Gastroenterology and Hepatology

ISSN: 2468-1253

Journal Home

Journal Guideline

The Lancet Gastroenterology and Hepatology Q1 Unclaimed

Elsevier Ltd. United Kingdom
Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

The Lancet Gastroenterology and Hepatology is a journal indexed in SJR in Gastroenterology and Hepatology with an H index of 49. It has an SJR impact factor of 4,897 and it has a best quartile of Q1. It has an SJR impact factor of 4,897.

The Lancet Gastroenterology and Hepatology focuses its scope in these topics and keywords: bowel, gastrointestinal, hepatitis, chronic, multicentre, extent, infectionfuture, inflammation, exploration, life, ...

Type: Journal

Type of Copyright:

Languages:

Open Access Policy:

Type of publications:

Publication frecuency: -

Price

- €

Inmediate OA

NPD

Embargoed OA

- €

Non OA

Metrics

The Lancet Gastroenterology and Hepatology

4,897

SJR Impact factor

49

H Index

234

Total Docs (Last Year)

617

Total Docs (3 years)

4263

Total Refs

3209

Total Cites (3 years)

240

Citable Docs (3 years)

4,86

Cites/Doc (2 years)

18,22

Ref/Doc

Aims and Scope


bowel, gastrointestinal, hepatitis, chronic, multicentre, extent, infectionfuture, inflammation, exploration, life, harms, living, locat, magnetic, martin, metric, newly, noninferiority, parts, enterography, endoscopysofosbuvirvelpatasvir, appendicitis, cessation, chills, controlled, corddiagnostic, crohns, cut, diagnosed, diagnosis, directions, disease, diseasespare, early, endoscopy,



Best articles by citations

15th European Crohn's and Colitis Organisation Congress

View more

Resolving gastric cancer aetiology: an update in genetic predisposition

View more

The influence of the brain-gut axis in inflammatory bowel disease and possible implications for treatment

View more

Treating hepatitis C virus in patients with chronic renal failure

View more

Orantinib versus placebo combined with transcatheter arterial chemoembolisation in patients with unresectable hepatocellular carcinoma (ORIENTAL): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study

View more

Liver diseases in the Asia-Pacific region: a Lancet Gastroenterology & Hepatology Commission

View more

Hepatitis C incidence 3 years after implementation of an educate, test, and treat programme in an Egyptian village

View more

Beyond the Milan criteria for liver transplantation in children with hepatic tumours

View more

Decision making for liver biopsy in NASH, not so FAST?

View more

Probiotics: elixir or empty promise?

View more

Fermented foods: fad or favourable addition to the diet?

View more

Detection of colorectal adenomas with a real-time computer-aided system (ENDOANGEL): a randomised controlled study

View more
SHOW MORE ARTICLES

My life with achalasia

View more

Hepatitis C treatment and liver cancer recurrence: cause for concern?

View more

Safety and efficacy of AMG 714 in patients with type 2 refractory coeliac disease: a phase 2a, randomised, double-blind, placebo-controlled, parallel-group study

View more

Anti-TNF treatment failure: drug levels, immunogenicity, or both?

View more

Pancreaticobiliary maljunction and congenital biliary dilatation

View more

Examining Britain's "drink problem"

View more

Upper gastrointestinal endoscopy: can we cut the cord?

View more

Eliminating hepatitis C in Europe

View more

Mechanisms of molecular resistance and predictors of response to biological therapy in inflammatory bowel disease

View more

Samuel Gee: the modern era for coeliac disease

View more

Apps: solutions to sociological and health problems

View more

Incidence of cirrhosis in young birth cohorts in Canada from 1997 to 2016: a retrospective population-based study

View more

Comments

No comments ... Be the first to comment!

FAQS